Nanogen's Q2 Revenues Spike 63 Percent, Loss Widens on Consolidation Costs | GenomeWeb
NEW YORK (GenomeWeb News) - Nanogen yesterday said second-quarter revenues increased 63 percent as R&D spending increased 15 percent and its net loss increased 3 percent.
 
Total receipts for the three months ended June 30 increased to $10.3 million from $6.3 million year over year.
 
The company said product-related revenue rose 32 percent to $5.3 million from $4 million, and income from licensing and royalties increased 13 percent to $2.1 million from $1.8 million.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.